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Abstract The  concept  of  personalized  medicine  is  not 
new. It is being discussed with increasing interest in the 
medical, scientific, and general media because of the avail-
ability of advanced scientific and computational technolo-
gies, and the promise of the potential to improve the tar-
geting and delivery of novel medicines. It is also being 
seen as one approach that may have a beneficial impact 
on reducing health care budgets. But what are the chal-
lenges that need to be addressed in its implementation in 
the clinic? This article poses some provocative questions 
and suggests some things that need to be considered.
“It is much more important to know what kind of patient 
has a disease than to know what kind of disease a pa-
tient has” 
Caleb Parry, 18th century physician
The concept of personalized medicine has been around at 
least since the late 1990s. Then, ideas of rational drug de-
sign tailored to genomic profiles, or therapies developed to 
target individual genetic variation evolved from hopes and 
expectations raised by advances heralded directly or indi-
rectly by the Human Genome Project, which undoubtedly 
has revolutionized our approach to biomedical research. 
But the aspirations that prevailed at the birth of the Ge-
nome Project anticipated more rapidly the delivery of safer, 
more effective medicines targeted more intelligently. This 
has just not been realized in the ensuing years. Our under-
standing has moved on from there and we now know that 
it is not only about genes; instead we now understand that 
emerging phenotypes in complex diseases are entirely de-
pendent on the dynamics of interaction between genes 
and broader environmental, epigenetic influences.
But what does personalized medicine actually mean? It is 
a phrase that can be interpreted in a variety of ways, and 
anyway is it not the case that medical practice has always 
been “personalized”? Many physicians would certainly ar-
gue that is the case, but in general it is accepted that it is 
an approach to improve the delivery of novel therapies tai-
lored to the needs of individual patients.
So how does the current view of personalized medicine, 
increasingly championed as the route to improved health 
care, differ from current medical practice? Today, medi-
cine is reactive, responding to the diagnosis of diseases 
late in their evolution, when they become symptomatic 
or at worst end stage. The move to a more predictive and 
preventive strategy, which lies at the heart of a personal-
ized approach, embraces the concept of “right medicine, 
right patient, right time,” and is the driver for approaches 
that seek to integrate information from a variety of “-omic” 
sources, genetics, and lifestyle data. Some advocate that 
personal, targeted therapy will be driven by information 
derived from individual personal genome sequences (and 
companies have been established to deliver these); others 
believe that the approach is more likely to be one using 
current technologies to segment or stratify patient groups, 
using profiles that will identify those who are more likely to 
respond to treatments. In truth, both sequence/mutation-
based rational therapies and stratified treatment regimes 
will emerge depending on the nature of the disease and 
what is practically feasible.
And what is practically feasible right now? Enormous ad-
vances have been made in recent years in developing a 
wide range of biomedical technologies, which, when ap-
plied in the research setting, have contributed to the de-
scription of diseases in increasingly fine molecular detail, 
and have helped to generate a tsunami of information. In 
contrast, clinical practice has largely remained reliant on 
the assessment of higher level phenotypic criteria and 
the  use  of  algorithms  to  evaluate  risk  probabilities, 
rather than on the use of a deeper understanding 
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of disease mechanisms gleaned from these technologi-
cal advances. So, while many technologies are available 
for use, a gulf exists between exemplification of their po-
tential in the research laboratory and their application in 
clinical practice, and this will influence what is considered 
by the jobbing physician to be practically feasible today. It 
may seem heretical to say it, but while many excellent re-
search articles have been written in high impact journals, 
pushing the frontiers of scientific information and knowl-
edge ever further forward, the intellectual advances alone 
are of little practical value unless they have an impact on 
medical practice or the crippling economics of health care. 
The challenge, therefore, is to find ways of translating the 
potential of cutting edge research excellence into clinical 
reality for the benefit of the patient and, ultimately, health 
care systems in general, in ways that can be incorporated 
relatively easily into routine medical practice by busy, prag-
matic, conservative health care professionals, and without 
escalating costs.
And how is this to be achieved? It is interesting to note 
that many, if not all of the examples cited when discussing 
personalized medicine strategies, refer to studies in can-
cer. In the late 1990s, approvals of Gleevec and Herceptin 
raised hopes for a more rational targeted and personalized 
approach to therapy. More recently, innovative medicines 
targeting mutations in bRaf and anaplastic lymphoma ki-
nase have been launched together with companion di-
agnostics. It is clear that the strong genetic drivers of dis-
ease progression in cancer provide an excellent platform 
to test and exemplify many of the technologies that might 
be applied routinely in personalization strategies for other 
diseases. But I would argue that these are very specialized 
cases because of the strong underlying genetic influenc-
es: if they are not themselves examples of diseases arising 
from major single gene defects, where mutation analysis 
has become part of routine clinical practice, neither are 
they the same as complex multifactorial diseases, where 
the interaction of a range of genes of small effect and envi-
ronmental factors contribute to the emerging phenotype. 
While cancers are undoubtedly major causes of morbidity 
and mortality, and are diseases that raise many emotive 
debates on the relative costs and benefits of treatment in 
the context of quality of life, it is arguable that they are not 
the diseases that pose the greatest burden on health care 
budgets (Figure 1). The combined cost of inpatient and 
outpatient treatment, care, and loss of economic produc-
tivity in chronic, debilitating diseases such as circulatory 
and  respiratory  disease,  dementia,  diabetes  and  arthri-
tis imposes a major drain on health care budgets. These 
complex multifactorial diseases are arguably more impor-
tant to address in the context of personalization strategies 
if benefit to the greater proportion of populations and the 
consequent impact on reducing health care costs is to be 
achieved.
This presents a significant problem for health care budgets 
in the 21st century. According to World Health Organiza-
tion statistics (1), there is a disproportionately greater prev-
alence in the elderly of chronic, complex diseases that are 
debilitating and difficult to treat: cancer and heart diseases 
appear more frequently in 70-75-year olds than other age 
groups; 80% of circulatory diseases appear in the over 65s; 
and the risk of developing dementia rises steeply after the 
age of 60, with prevalence in men being greater due to in-
creased longevity. The world population is increasing at a 
rate of about 80 million people per year and is estimated 
to reach around 8 billion by the year 2025. By that time, 
the proportion of those over the age of 65 is expected to 
represent 10% of the population, or some 800 million peo-
ple. In Europe, the proportion of over 65s by that time will 
be closer to 25%. Thus, personalization strategies need to 
be focusing on making an impact here if they are to have 
genuine value to patient, health care systems, and national 
economies.
These diseases are areas of major focus for novel therapies, 
and have been for some time, but the success of bring-
ing innovative medicines to market over the last couple 
of decades has been poor, despite the wealth of technical 
advancements experienced in medical sciences. Pharma-
ceutical industry figures (2) show that the full cost of bring-
ing a new medicine to market has risen sharply since 1975, 
from some US $140 million to an estimated US$1300 mil-
lion by 2006 (Figure 2). In contrast, the success of delivery 
of new medicines to market has declined significantly over 
Figure 1. Disability (light gray) and mortality (dark gray) contribution to the total 
disease burden for selected diseases in europe (WHO subregion eur A). Source: 
Kobelt g, Kasteng F. Access to innovative treatments in rheumatoid arthritis in europe, 
reproduced with permission from The Pharmaceutical industry in Figures, eFPiA, 2010 
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the same period, despite our increased “knowledge” of dis-
ease mechanisms and pathways (Figure 3).
Why are effective treatments for these complex diseases so 
hard to find? One major factor is, surprisingly, our relatively 
poor understanding of biology.
“Doctors are men who prescribe medicines, of which they 
know little, to cure diseases of which they know less in hu-
man beings of whom they know nothing”
François-Marie Arouet (Voltaire, 1694-1778)
All of the technological advances over the last 20 years 
have done much to generate lots of information and data, 
but they have had little impact on improving our under-
standing of how individual components interact to enable 
function. Diseases are not the products of dysfunction in 
isolated individual entities or linear pathways; they arise 
from perturbations in complex dynamic networks that shift 
from patterns representing normal function to others that 
give rise to disease. Complex multifactorial diseases are not 
the result of a malfunction in a single target protein and are 
unlikely to be resolved by targeting a single gene product. 
However, the search for and development of new medi-
cines focuses on reductionist, cell, and molecular screens 
that capitalize on the highly detailed information on tar-
gets that has been acquired as a result of the advances in 
molecular and cellular biology. The tendency has been to 
refine the optimization of novel compounds against iso-
lated targets removed from their physiological networks, 
and then to “validate” and build associations to function in 
the human via a series of cellular and animal models, many 
of which are not faithful representations of the true physi-
ological context in which the compound is ultimately in-
tended to operate. There has also been an increasing prob-
lem with the toxic side effects of new medicines, although 
this has recently been improved significantly in the preclin-
ical phase. Failure of medicines in development, especially 
in phase II or phase III is extremely costly and, according to 
recent statistics, is now largely related to a failure in efficacy 
(3). That is, the drug is not doing what it is supposed to do 
in the patient. So, even though we think we know a lot 
about the building blocks of biological systems, we actu-
ally know very little about how those building blocks 
operate in the physiological networks that underpin 
Figure 2. estimated full cost of bringing a new chemical or 
biological entity to market (uS$ million – year 2005 uS$). 
Source: DiMasi JA, grabowski Hg. The cost of biopharmaceuti-
cal r/D: is biotech different, reproduced with permission from 
The Pharmaceutical industry in Figures, eFPiA, 2010 edition (2).
Figure 3. Number of new chemical or biological entities 
(1990-2009). Source: SCriP-eFPiA calculations (according to 
nationality of mother company), reproduced with permis-
sion from The Pharmaceutical industry in Figures, eFPiA, 2010 
edition (2). europe – dark gray; uSA – white; Japan – horizontal 
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diseases, their progression, and the effect of any interven-
tions that seek to improve outcome.
Putting it bluntly, how can such reductionist approaches 
possibly help us predict and test, let alone understand how 
a new medicine will work, when given to a patient in the 
target treatment group, which, in the case of the major ill-
nesses that are being targeted by personalization strate-
gies, is likely to be over 65, with a number of co-morbidities 
and already taking a number of other medications? So is it 
really that surprising to encounter failures in efficacy in the 
clinic? In our understandable enthusiasm to follow the path 
laid by the genome revolution, generating an evermore in-
tricate map of human disease at the molecular level, we ap-
pear to have forgotten, or at least relegated the importance 
of an understanding of the physiological context.
The need now is undoubtedly to find ways to understand 
the dynamics of the complex interactions within the bio-
logical networks that underpin normal function, and the 
way in which these are perturbed in disease. We need 
to understand how targets operate not in isolation, but 
in physiological networks and, as importantly, within the 
context of the elderly who will likely present at clinic with a 
number of co-morbidities and taking a number of medica-
tions. This can be achieved through adopting integrative 
systems approaches that address the dynamics of disease 
networks, rather than analyzing static functions in isola-
tion. The potential for these approaches to have an impact 
on 21st century medical practice is not in doubt: there are 
many publications clearly demonstrating this at the aca-
demic level, but what is lacking is sufficient evidence of its 
application in the real world and its ability to be reduced to 
practice. The challenge that faces us now, therefore, is how 
to evaluate and assess the added value that these advanc-
es in science bring to existing medical practice, and then 
to find ways of exploiting them routinely in the clinic. This 
task is complex and challenging, as it is dependent more 
than ever on the need to bring exploratory, blue skies sci-
ence and busy, practicing physicians together to test the 
potential of, and troubleshoot, unproven technologies.
Those advocating a multidisciplinary approach, integrating 
the acquired molecular information by bringing together 
biology with mathematics, engineering, and physics have 
an increasingly strong voice in the biosciences. The use of 
mathematical models to tackle network complexity and 
to simulate and predict function is now seen as an in-
evitable evolution in biology. Indeed, industry analysts 
have gone so far as to say that it is an essential com-
ponent of the changes that need to take place in the cur-
rent pharmaceutical industry business model if it is to sur-
vive the challenges it faces (4).
And what about personalization? Historically the pharma-
ceutical  industry  blockbuster  model  has  been  to  sell  its 
products to as many patients as possible, so there has been 
a natural resistance to approaches that would segment their 
markets. But reality is now beginning to bite: if it can be 
shown that medicines can be targeted more accurately us-
ing new technologies, then it will not be long before payers 
begin to reimburse only in cases where companion diag-
nostics can demonstrate an increased potential for efficacy. 
The question here is, who will pay for the development of 
the diagnostic test and how will that get reimbursed?
With the increasing emphasis on personalization of ther-
apies and the segmentation or stratification of treatment 
populations, the integrative systems approach described 
above is equally important in the context of biomarker 
and diagnostics development, helping to identify the nee-
dles in the haystack of potential options. The fundamental 
need, and the major challenge for biology and medicine 
now, is to improve our understanding of the connection 
between  genetics  and  emerging  phenotype  through  a 
better view of physiological systems behavior. This will re-
quire, not just the adoption of novel, cutting edge tech-
nologies, but a cultural change to embrace new business 
models and educational approaches, not just in the biosci-
ences, but also in medicine.
“It’s not the strongest species that survive, nor the most 
intelligent, but the ones most responsive to change”
Charles Darwin
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